BRIEF-Chemocentryx says treatment with CCX168 successful in achieving clinical efficacy endpoints

* Chemocentryx announces presentation of positive results

from Phase II ANCA-associated vasculitis clear trial of orally

administered complement 5a receptor inhibitor CCX168 at the 53rd

ERA-EDTA congress

Read more